Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Reckitt Benckiser Group PLC on Thursday framed emerging markets as a priority in growing its Core business, ahead of an investor seminar.
This segment includes Reckitt’s ‘powerbrands’ - such household names as Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen, Strepsils, Vanish and Veet.
Shares in the Slough, England-based firm rose 0.5% to 5,956.00 pence on Thursday morning in London.
The consumer health and hygiene product seller is aiming for high single-digit revenue growth from emerging markets, on a like-for-like basis.
This will support its medium-term target of Core LFL sales growth ranging from 4% to 5%, the firm said. The 2025 target stands between 3% and 4%, with Core LFL sales in 2024 having grown 3.3.%.
In 2024, the Core Reckitt business contributed 71% to net revenue, with emerging market comprising roughly 39% of Core sales.
Reckitt stressed that ‘no new material financial or trading information’ will be shared at its investor seminar on Thursday.
Copyright 2025 Alliance News Ltd. All Rights Reserved.